- A moving average of Short volume ratio is at a recent 2 week high. A high short volume ratio indicate selling presures.
- RSI is at a high level of 86. A high level of RSI indicates the stock is overbought.
- MACD is crossing MACD signal line at 3.2. MACD crossing signal line is bullish signal.
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
On Wednesday, Ligand Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 93 to 97.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) provided today details of its plans to report fourth quarter 2020 financial results on February 3, 2021. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
A rebounding stock market closed near session highs Tuesday, as the S&P 500 and Dow Jones Industrial Average appeared to get through a key test.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported that the company will receive a $1.5 million milestone payment from Merck triggered by the U.S. Food and Drug Administration’s (FDA’s) acceptance for review of a biologics license application (BLA) for V114, an investigational 15-valent pneumococcal conjugate vaccine candidate for the prevention of pneumococcal disease in adults.
Coronavirus vaccine updates from Moderna (MRNA) and Pfizer (PFE)/BioNTech (BNTX) continue to take centerstage in the biotech sector.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today a collaboration and license agreement between its subsidiary, Icagen, and GlaxoSmithKline (GSK) to leverage Icagen’s unique expertise in small molecule therapeutics targeting transmembrane proteins. This collaboration will utilize the Icagen discovery technology to identify and develop inhibitors of a specific genetically-validated molecular target relevant to neurological diseases.
We at Insider Monkey have gone over 817 13F filings that hedge funds and prominent investors are required to file by the SEC The 13F filings show the funds’ and investors’ portfolio positions as of September 30th. In this article, we look at what those funds think of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) based on that […]
Companies including Ligand Pharmaceuticals and LendingTree are expected by analysts to post double-digit revenue growth next year.